Targeted cancer therapy: What if the driver is just a messenger?

Cell Cycle

Volumn 10, Issue 22, 2011, Pages 3830-3833

  Schatz, Jonathan H ^a,b   Wendel, Hans Guido ^a  

^a Cancer Biology and Genetics Program   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cancer; eIF4E; Lymphoma; Targeted therapy; Translation

Indexed keywords

CYCLIN D1; FLAVAGLINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MYC PROTEIN; PLANT MEDICINAL PRODUCT; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; PROTEIN MCL 1; RAPALOG; RNA HELICASE; SGI 1773; SGI 1776; SILVESTROL; UNCLASSIFIED DRUG; VEMURAFENIB;

AGLAIA; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; CARCINOGENICITY; CARDIOTOXICITY; CHROMOSOME TRANSLOCATION; DRUG WITHDRAWAL; FOLLICULAR LYMPHOMA; HUMAN; IN VITRO STUDY; MELANOMA; METASTASIS; NONHODGKIN LYMPHOMA; PROTEIN PHOSPHORYLATION; REVIEW; TOXICITY; XENOGRAFT;

EID: 81855212716     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.22.18288     Document Type: Review

References (26)

1. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res 2011; 17:1674-83; PMID:21307148; DOI:10.1158/1078-0432. CCR-10-2922.
2. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 2011; 17:1658-63; PMID:21447722; DOI:10.1158/1078-0432.CCR-10-0174.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; DOI:10.1056/NEJMoa1103782.
4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-17; PMID:17151364; DOI:10.1056/ NEJMoa062867.
5. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14:2895-9; PMID:18483355; DOI:10.1158/1078-0432.CCR-07- 2248.
6. Sawyers CL. Cancer: mixing cocktails. Nature 2007; 449:993-6; PMID:17960228; DOI:10.1038/449993a.
7. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19:575-86; PMID:21575859; DOI:10.1016/j.ccr.2011.04.008.
8. Alberghina L, Hofer T, Vanoni M. Molecular networks and system-level properties. J Biotechnol 2009; 144:224-33; PMID:19616593; DOI:10.1016/j.jbiotec. 2009.07.009.
9. Blagden SP, Willis AE. The biological and therapeutic relevance of mRNA translation in cancer. Nature reviews. Nat Rev Clin Oncol 2011; 8:280-91.
10. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 1990; 345:544-7; PMID:2348862; DOI:10.1038/345544a0.
11. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7; PMID:15029198; DOI:10.1038/nature02369.
12. Livingstone M, Atas E, Meller A, Sonenberg N. Mechanisms governing the control of mRNA translation. Phys Biol 2010; 7:21001; PMID:20463379; DOI:10.1088/1478-3975/7/2/021001.
13. Rhoads RE, Joshi-Barve S, Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: effects on mRNA discrimination, cellular growth rate and oncogenesis. Prog Nucleic Acid Res Mol Biol 1993; 46:183-219; PMID:8234784; DOI:10.1016/S0079-6603(08)61022-3.
14. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003; 20:265-73; PMID:12741684; DOI:10.1023/A:1022943419011.
15. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21:3232-7; PMID:18055695; DOI:10.1101/gad.1604407.
16. Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011; 208:1799-807; PMID:21859846; DOI:10.1084/jem.20110846.
17. Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS. Pim-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor elF-4E. Cell Growth Differ 1997; 8:1371-80; PMID:9419425.
18. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455:679-83; PMID:18716624; DOI:10.1038/nature07260.
19. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008; 118:2651-60; PMID:18551192.
20. Schatz JH. Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin's Lymphoma: Results, Biology and Development Strategies. Curr Oncol Rep 2011; 13:398-406; PMID:21755275; DOI:10.1007/s11912-011-0187-7.
21. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003; 17:1841-54; PMID:12869584; DOI:10.1101/gad.1105003.
22. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005; 105:4477-83; PMID:15705789; DOI:10.1182/blood-2004-09-3706.
23. Gómez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, Gonzalez-Menchen A, Martinez- Climent JA, et al. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood 2011; In press; PMID:21937691; DOI:10.1182/blood-2011-03-344374.
24. Chiarle R, Zhang Y, Frock RL, Lewis SM, Molinie B, Ho YJ, et al. Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells. Cell 2011; 147:107-19; PMID:21962511; DOI:10.1016/j.cell.2011.07.049.
25. Klein IA, Resch W, Jankovic M, Oliveira T, Yamane A, Nakahashi H, et al. Translocation-Capture Sequencing Reveals the Extent and Nature of Chromosomal Rearrangements in B Lymphocytes. Cell 2011; 147:95-106; PMID:21962510; DOI:10.1016/j.cell.2011.07.048.
26. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, et al. Antitumor activity and mechanism of action of the cyclopenta[b] benzofuran, silvestrol. PLoS ONE 2009; 4:5223; PMID:19401772; DOI :10.1371/journal.pone.0005223.